About Beta-2 adrenergic receptor
Beta-2 adrenergic receptor (ADRB2) is a protein
from Homo sapiens identified by UniProt accession
P07550, 413 residues long.
MolForge cross-references it against 0 known binders and
715 disease associations.
Target properties
| Protein name | Beta-2 adrenergic receptor |
| UniProt accession | P07550 |
| Gene | ADRB2 |
| Organism | Homo sapiens |
| Length | 413 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (715)
Diseases linked to this target (Open Targets).
- chronic obstructive pulmonary disease · score 0.63
- asthma · score 0.61
- myocardial infarction · score 0.61
- migraine disorder · score 0.61
- open-angle glaucoma · score 0.61
- hypertension · score 0.61
- glaucoma · score 0.61
- Sepsis · score 0.60
- hypotension · score 0.60
- Airway obstruction · score 0.60
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P07550-F1 | alphafold | PREDICTED | 79.14 | — |
Amino-acid sequence (413 residues)
MGQPGNGSAF LLAPNGSHAP DHDVTQERDE VWVVGMGIVM SLIVLAIVFG NVLVITAIAK FERLQTVTNY FITSLACADL VMGLAVVPFG AAHILMKMWT FGNFWCEFWT SIDVLCVTAS IETLCVIAVD RYFAITSPFK YQSLLTKNKA RVIILMVWIV SGLTSFLPIQ MHWYRATHQE AINCYANETC CDFFTNQAYA IASSIVSFYV PLVIMVFVYS RVFQEAKRQL QKIDKSEGRF HVQNLSQVEQ DGRTGHGLRR SSKFCLKEHK ALKTLGIIMG TFTLCWLPFF IVNIVHVIQD NLIRKEVYIL LNWIGYVNSG FNPLIYCRSP DFRIAFQELL CLRRSSLKAY GNGYSSNGNT GEQSGYHVEQ EKENKLLCED LPGTEDFVGH QGTVPSDNID SQGRNCSTND SLL
Explore Beta-2 adrenergic receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets